The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases

Furukawa,Kenei; Shiba,Hiroaki; Haruki,Koichiro; Fujiwara,Yuki; Iida,Tomonori; Mitsuyama,Yoshinobu; Ogawa,Masaichi; Ishida,Yuichi; Misawa,Takeyuki; Yanaga,Katsuhiko

doi:10.3892/ol.2012.722

The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases

Authors:
- Kenei Furukawa
- Hiroaki Shiba
- Koichiro Haruki
- Yuki Fujiwara
- Tomonori Iida
- Yoshinobu Mitsuyama
- Masaichi Ogawa
- Yuichi Ishida
- Takeyuki Misawa
- Katsuhiko Yanaga
View Affiliations

Affiliations: Department of Surgery, The Jikei University School of Medicine, Tokyo 105-8461, Japan
Published online on: May 17, 2012 https://doi.org/10.3892/ol.2012.722
Pages: 324-328

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Systemic inflammation as evidenced by the Glasgow prognostic score (GPS) predicts cancer-specific survival in various types of cancer. The aim of this study was to evaluate the significance of GPS in patients with both synchronous and metachronous unresectable colorectal cancer liver metastases (CRLM). The subjects were 40 patients who were diagnosed as having unresectable CRLM between March 2000 and August 2010 at Jikei University Hospital. For the assessment of systemic inflammatory response using the GPS, the patients were classified into three groups: patients with normal albumin (≥3.5 g/dl) and normal CRP (≤1.0 mg/dl) as GPS 0 (n=27), those with low albumin (<3.5 g/dl) or elevated CRP (>1.0 mg/dl) as GPS 1 (n=6), and both low albumin (<3.5 g/dl) and elevated CRP (>1.0 mg/dl) as GPS 2 (n=7). We retrospectively investigated the relationship between patient characteristics including GPS and survival using univariate and multivariate analyses. Results of the univariate analysis revealed that absence of primary tumor resection (p=0.0161), absence of systemic chemotherapy (p=0.0119), serum carcinoembroynic antigen (CEA) of ≥100 ng/ml (p=0.0148), serum carbohydrate antigen (CA)19-9 of ≥100 U/ml (p<0.0001) and GPS 2 (p=0.0362) were significant predictors of poor survival. Results of the multivariate analysis revealed that serum CEA of ≥100 ng/ml (p=0.0015), CA19-9 of ≥100 U/ml (p<0.0001) and GPS 2 (p=0.0042) were independent predictors. In conclusion, GPS at diagnosis of unresectable CRLM is an independent prognostic predictor of overall survival.

View Figures

View References

1	Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MW: Colorectal cancer. Lancet. 365:153–165. 2005. View Article : Google Scholar
2	O’Reilly DA and Poston GJ: Colorectal liver metastases: current and future perspectives. Future Oncol. 2:525–531. 2006.
3	Rodgers MS and McCall JL: Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review. Br J Surg. 87:1142–1155. 2000. View Article : Google Scholar : PubMed/NCBI
4	Martin LW and Warren RS: Current management of colorectal liver metastases. Surg Oncol Clin North Am. 9:853–876. 2000.PubMed/NCBI
5	Penna C and Nordlinger B: Colorectal metastasis (liver and lung). Surg Clin North Am. 82:1075–1090. 2002. View Article : Google Scholar : PubMed/NCBI
6	Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, Mochizuki H and Yamamoto J: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 46:S22–S31. 2003.PubMed/NCBI
7	Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P and Jaeck D: Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 77:1254–1262. 1996. View Article : Google Scholar : PubMed/NCBI
8	Seifert JK, Böttger TC, Weigel TF, Gönner U and Junginger T: Prognostic factors following liver resection for hepatic metastases from colorectal cancer. Hepatogastroenterology. 47:239–246. 2000.PubMed/NCBI
9	Fong Y, Fortner J, Sun RL, Brennan MF and Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 230:309–321. 1999. View Article : Google Scholar : PubMed/NCBI
10	Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, Yamamoto J and Imamura H: Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg. 231:487–499. 2000. View Article : Google Scholar : PubMed/NCBI
11	Jonas S, Thelen A, Benckert C, Spinelli A, Sammain S, Neumann U, Rudolph B and Neuhaus P: Extended resections of liver metastases from colorectal cancer. World J Surg. 31:511–521. 2007. View Article : Google Scholar : PubMed/NCBI
12	Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC and Bachellier P: A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 240:1037–1049. 2004. View Article : Google Scholar
13	Wood CB, Gillis CR and Blumgart LH: A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol. 2:285–288. 1976.PubMed/NCBI
14	Wagner JS, Adson MA, Van Heerden JA, Adson MH and Ilstrup DM: The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment. Ann Surg. 199:502–508. 1984. View Article : Google Scholar : PubMed/NCBI
15	McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 67:257–262. 2008. View Article : Google Scholar : PubMed/NCBI
16	McMillan DC, Crozier JE, Canna K, Angerson WJ and McArdle CS: Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 22:881–886. 2007. View Article : Google Scholar : PubMed/NCBI
17	Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal carcinoma. 1st English ed. Kanehara Co., Ltd.; Tokyo: 1997
18	Sobin LH and Wittekind: UICC TNM classification of malignant tumors. 5th edition. John Wiley & Sons, Inc; New York: 1997
19	Jaeck D, Bachellier P, Guiguet M, Boudjema K, Vaillant JC, Balladur P and Nordlinger B: Long-term survival following resection of colorectal hepatic metastases. Association Française de Chirurgie. Br J Surg. 84:977–980. 1997.PubMed/NCBI
20	Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 89:1028–1030. 2003. View Article : Google Scholar : PubMed/NCBI
21	Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 90:1704–1706. 2004.PubMed/NCBI
22	Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C and McMillan DC: Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 94:227–230. 2006.PubMed/NCBI
23	Crumley AB, McMillan DC, McKernan M, McDonald AC and Stuart RC: Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 94:637–641. 2006.PubMed/NCBI
24	Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW and McKay CJ: Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 6:450–453. 2006. View Article : Google Scholar : PubMed/NCBI
25	Ramsey S, Lamb GW, Aitchison M, Graham J and McMillan DC: Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. 109:205–212. 2007. View Article : Google Scholar : PubMed/NCBI
26	Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG and McMillan DC: Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 97:1266–1270. 2007. View Article : Google Scholar : PubMed/NCBI
27	Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 343:905–914. 2000. View Article : Google Scholar : PubMed/NCBI
28	Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
29	De Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N and Krulik M: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 33:214–219. 1997.
30	Poston GJ: The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Eur J Surg Oncol. 31:325–330. 2005. View Article : Google Scholar : PubMed/NCBI